A Phase 2 interventional study of Saroglitazar magnesium 1 mg and Saroglitazar magnesium 2 mg in Non-Alcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis, sponsored by Zydus Therapeutics Inc.. Completed at 18 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-10-24.
Sponsored by Zydus Therapeutics Inc. (part of Zydus Lifesciences Limited) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States — 60 open to participants now, 93 under way, 13 of them phase 3. Non-alcoholic Fatty Liver Disease · United States.
Among the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, this one is the 156th largest by enrollment of the 460 interventional ones that give a count, is one of 26 that started in 2017, is one of 192 in phase 2, and was the 201st registered.
1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.
Browse Non-alcoholic Fatty Liver Disease studies →60 of the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in United States
Ages 18–75
Regeneron Pharmaceuticals · Sites in United States, Puerto Rico, United Kingdom
Ages 18–75
Columbia University · Sites in United States
Ages 18–65
Regeneron Pharmaceuticals · Sites in United States
Ages 18–75
GlaxoSmithKline · Sites in United States
Ages 18–70
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
547 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 93 · Phase 2 213 · Phase 3 36 · Phase 4 13
First in 2000; this study’s year is marked. 26 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 106 is above the median of 60 across 1,176 interventional studies indexed under Non-alcoholic Fatty Liver Disease.
Median enrollment 56 across the 460 interventional studies, 90 across the 85 observational. Of the 420 that completed or were terminated, 216 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
246 of 547 have an industry lead sponsor. The 10 most frequent:
This study is registered under Zydus Therapeutics Inc., one of the names counted as Zydus Lifesciences Limited. Under that name alone:
Zydus Therapeutics Inc. is the lead sponsor of 19 studies on the registry; 5 are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 6 (50%) have results posted.
Zydus Lifesciences Limited has 7 studies filed under Non-alcoholic Fatty Liver Disease — fewer than ten, so there is no comparison to draw.
22 of the studies in Non-alcoholic Fatty Liver Disease with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04951219Phase 3Madrigal Pharmaceuticals, Inc.A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE) | 2027-03 |
| NCT04833140Phase 3Massachusetts General HospitalEstrogen Administration for the Treatment of NASH in Postmenopausal Women | 2027-07-09 |
| NCT00983463Vanderbilt UniversityAbundance and Distribution of Lipids and Proteins in Nonalcoholic Fatty Liver Disease (NAFLD) | 2026-11 |
| NCT05165706Stanford UniversityLongitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance | 2026-11-30 |
| NCT05067621Yale UniversitySemaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease | 2026-12 |
Add all 22 to your calendar (.ics) → With an account.
Among the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a randomized, double-blind, placebo-controlled study in up to 104 patients with a diagnosis of Non-alcoholic fatty Liver disease (NAFLD) and/or Non-alcoholic steatohepatitis (NASH). The study will be conducted over a period of up to 22 weeks and will include an optional Prescreening, Screening (Days -35 to -7) Phase, a 16-week Treatment Phase following randomization on Day 1. Patients will be randomly assigned in a ratio of 1:1:1:1 to receive Saroglitazar Magnesium 1mg or 2 mg or 4 mg or matching placebo once daily in the morning before breakfast for 16 Weeks. The primary endpoint of the study is percentage change from baseline in serum Alanine transaminase (ALT) levels at Week 16 in the Saroglitazar Magnesium groups as compared to the placebo group.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Presence of alternative causes of fatty liver, including:
Unstable cardiovascular disease, including:
Any of the following laboratory values:
Pregnancy-related exclusions, including:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Saroglitazar magnesium 1 mg tablet orally once daily in the morning before breakfast for 16 weeks.
Drug: Saroglitazar magnesium 1 mg
Saroglitazar magnesium 2 mg tablet orally once daily in the morning before breakfast for 16 weeks.
Drug: Saroglitazar magnesium 2 mg
Saroglitazar magnesium 4 mg tablet orally once daily in the morning before breakfast for 16 weeks.
Drug: Saroglitazar magnesium 4 mg
Placebo tablet orally once daily in the morning before breakfast for 16 weeks.
Drug: Placebos
Patients randomly assigned to this group will receive Saroglitazar magnesium 1 mg tablet orally once daily for 16 weeks.
Patients randomly assigned to this group will receive Saroglitazar magnesium 2 mg tablet orally once daily for 16 weeks.
Patients randomly assigned to this group will receive Saroglitazar magnesium 4 mg tablet orally once daily for 16 weeks.
Patients randomly assigned to this group will receive placebo tablet orally once daily for 16 weeks.
Percentage Change From Baseline in Serum Alanine Aminotransferase (ALT) Levels at Week 16
Percentage change from baseline in serum ALT levels at Week 16 in the Saroglitazar Magnesium groups as compared to the placebo group
Time frame: Baseline and Week 16
Change in Liver Fat Content as Measured by Magnetic Resonance Imaging-derived Proton Density-fat Fraction (MRI-PDFF)
Change in liver fat content as measured by magnetic resonance imaging-derived proton in Saroglitazar Magnesium groups as compared to the placebo group
Time frame: Baseline and Week 16
Proportion of Patients With Sustain Decrease in Serum ALT Levels
Proportion of patients with sustain decrease in serum ALT levels in Saroglitazar Magnesium groups as compared to the placebo group
Time frame: Week 16
Changes in Cytokeratin-18
Changes in cytokeratin-18 in Saroglitazar Magnesium groups as compared to the placebo group
Time frame: baseline and Week 16
Changes in Enhanced Liver Fibrosis
Changes in enhanced liver fibrosis in Saroglitazar Magnesium groups as compared to the placebo group The ELF Score is a liver fibrosis score that is calculated by use of an algorithm: ELF score score = -7.412 + (ln(HA)\*0.681) + (ln(P3NP)\*0.775) + (ln(TIMP1)\*0.494). HA=hyaluronic acid concentration P3NP=procollagen 3 amino terminal peptide concentration TIMP1=tissue inhibitor matrix metalloproteinase 1 concentration. All are measured in serum. The ELF score has been reported to show good correlations with fibrosis stages in chronic liver disease, with higher ELF scores associated with higher fibrosis stages. The ELF score is hence used as a prognostic marker for disease progression: ELF score \< 9.8 : Low risk of progression, ELF score 9.8 to \< 11.3 : Moderate risk of progression and ELF score \> = 11.3 : High risk of progression
Time frame: baseline and Week 16
Change in Aspartate Aminotransferase-to-platelet Ratio Index
Change in aspartate aminotransferase-to-platelet ratio index in Saroglitazar Magnesium groups as compared to the placebo group APRI was calculated as (\[AST level/AST upper limit of normal\]/ \[Platelet count 1\^09/L\]) ×100, where AST is aspartate aminotransferase. The aspartate transaminase to platelet ratio index (APRI) is used to assess the risk of liver fibrosis. Higher APRI score represents a higher risk of liver fibrosis
Time frame: Baseline and Week 16
Pharmacokinetics of Saroglitazar Magnesium: Maximum Plasma Concentration (Cmax)
Maximum plasma concentration (Cmax) of Saroglitazar
Time frame: PK sampling timepoints: Pre-dose (0.0), 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0, and 24 hours post-dose of Visit 7 (Week 16)
Time to Reach Maximum Plasma Concentration (Tmax)
Time to reach maximum plasma concentration (Tmax) of saroglitazar
Time frame: PK sampling timepoints: Pre-dose (0.0), 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0, and 24 hours post-dose of Visit 7 (Week 16)
Terminal Half-life (t1/2)
Terminal Half-life (t1/2) of saroglitazar
Time frame: PK sampling timepoints: Pre-dose (0.0), 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0, and 24 hours post-dose of Visit 7 (Week 16)
Area Under the Curve From the Time of Dosing to the Last Measurable Concentration (AUC0-t)
Area under the curve from the time of dosing to the last measurable concentration for saroglitazar
Time frame: PK sampling timepoints: Pre-dose (0.0), 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0, and 24 hours post-dose of Visit 3 (Week 0)
Area Under the Curve From the Time of Dosing to the Infinity (AUC 0-inf)
Area under the curve from the time of dosing to the infinity (AUC 0-inf) for Saroglitazar
Time frame: PK sampling timepoints: Pre-dose (0.0), 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0, and 24 hours post-dose of Visit 3 (Week 0)
Elimination Rate Constant (λz)
Elimination rate constant (λz) for saroglitazar
Time frame: PK sampling timepoints: Pre-dose (0.0), 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0, and 24 hours post-dose of Visit 7 (Week 16)
Apparent Volume of Distribution (Vd/F)
Apparent volume of distribution (Vd/F) for Saroglitazar
Time frame: PK sampling timepoints: Pre-dose (0.0), 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0, and 24 hours post-dose of Visit 7 (Week 16)
Apparent Clearance (CL/F)
Apparent clearance (CL/F) for Saroglitazar
Time frame: PK sampling timepoints: Pre-dose (0.0), 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0, and 24 hours post-dose of Visit 7 (Week 16)
Change in Quality of Life Assessed by the Short-Form 36 Health Survey
Quality of life will be assessed by the Short-Form 36 Health Survey The SF-36 is a multi-purpose, short-form health survey with 36 questions. It yields an 8-scale profile of functional health and well-being scores (domains) as well as psychometrically based physical and mental health summary measures. The SF-36 taps 8 health concepts: physical functioning, bodily pain, physical role functioning, emotional role functioning, emotional well-being, social functioning, vitality, and general health perceptions. The 8 scales are further summarized to 2 distinct higher-ordered clusters: the PCS and mental composite t-score (MCS). The range for all 8 domains as well as for the composite t-scores is from 0 to 100 with 100 as best possible health status and 0 as worst health status.
Time frame: baseline and 16 Week
Safety and Tolerability of Saroglitazar Magnesium
Number of participants with adverse events
Time frame: Baseline to Week 17
| Milestone | Saroglitazar Magnesium 1 mg | Saroglitazar Magnesium 2 mg | Saroglitazar Magnesium 4 mg | Placebos |
|---|---|---|---|---|
| Started | 26 | 25 | 27 | 28 |
| Completed | 26 | 20 | 27 | 25 |
| Not completed | 0 | 5 | 0 | 3 |
Percentage change from baseline in serum ALT levels at Week 16 in the Saroglitazar Magnesium groups as compared to the placebo group
| Percentage change | Saroglitazar Magnesium 1 mg | Saroglitazar Magnesium 2 mg | Saroglitazar Magnesium 4 mg | Placebo |
|---|---|---|---|---|
| Percentage Change From Baseline in Serum Alanine Aminotransferase (ALT) Levels at Week 16 | -26.2 ± 33.36 | -27.0 ± 26.52 | -44.9 ± 26.26 | 2.6 ± 32.06 |
Change in liver fat content as measured by magnetic resonance imaging-derived proton in Saroglitazar Magnesium groups as compared to the placebo group
| percentage of Liver fat | Saroglitazar Magnesium 1 mg | Saroglitazar Magnesium 2 mg | Saroglitazar Magnesium 4 mg | Placebo |
|---|---|---|---|---|
| Change in Liver Fat Content as Measured by Magnetic Resonance Imaging-derived Proton Density-fat Fraction (MRI-PDFF) | 0.53 ± 5.228 | -0.36 ± 4.297 | -4.21 ± 6.231 | -0.28 ± 5.409 |
Proportion of patients with sustain decrease in serum ALT levels in Saroglitazar Magnesium groups as compared to the placebo group
| Participants | Saroglitazar Magnesium 1 mg | Saroglitazar Magnesium 2 mg | Saroglitazar Magnesium 4 mg | Placebo |
|---|---|---|---|---|
| Proportion of Patients With Sustain Decrease in Serum ALT Levels | 22 | 22 | 26 | 14 |
Changes in cytokeratin-18 in Saroglitazar Magnesium groups as compared to the placebo group
| U/L | Saroglitazar Magnesium 1 mg | Saroglitazar Magnesium 2 mg | Saroglitazar Magnesium 4 mg | Placebo |
|---|---|---|---|---|
| Changes in Cytokeratin-18 | -3.0 ± 693.75 | -330.3 ± 590.37 | -64.1 ± 303.59 | 97.4 ± 437.10 |
Changes in enhanced liver fibrosis in Saroglitazar Magnesium groups as compared to the placebo group The ELF Score is a liver fibrosis score that is calculated by use of an algorithm: ELF score score = -7.412 + (ln(HA)\*0.681) + (ln(P3NP)\*0.775) + (ln(TIMP1)\*0.494). HA=hyaluronic acid concentration P3NP=procollagen 3 amino terminal peptide concentration TIMP1=tissue inhibitor matrix metalloproteinase 1 concentration. All are measured in serum. The ELF score has been reported to show good correlations with fibrosis stages in chronic liver disease, with higher ELF scores associated with higher fibrosis stages. The ELF score is hence used as a prognostic marker for disease progression: ELF score \< 9.8 : Low risk of progression, ELF score 9.8 to \< 11.3 : Moderate risk of progression and ELF score \> = 11.3 : High risk of progression
| units on a scale | Saroglitazar Magnesium 1 mg | Saroglitazar Magnesium 2 mg | Saroglitazar Magnesium 4 mg | Placebo |
|---|---|---|---|---|
| Changes in Enhanced Liver Fibrosis | -0.2 ± 0.78 | -0.3 ± 0.86 | -0.3 ± 0.72 | 0.4 ± 0.78 |
Change in aspartate aminotransferase-to-platelet ratio index in Saroglitazar Magnesium groups as compared to the placebo group APRI was calculated as (\[AST level/AST upper limit of normal\]/ \[Platelet count 1\^09/L\]) ×100, where AST is aspartate aminotransferase. The aspartate transaminase to platelet ratio index (APRI) is used to assess the risk of liver fibrosis. Higher APRI score represents a higher risk of liver fibrosis
| units on a scale | Saroglitazar Magnesium 1 mg | Saroglitazar Magnesium 2 mg | Saroglitazar Magnesium 4 mg | Placebo |
|---|---|---|---|---|
| Change in Aspartate Aminotransferase-to-platelet Ratio Index | -0.3 ± 0.56 | -0.2 ± 0.51 | -0.3 ± 0.47 | 0.1 ± 0.73 |
Maximum plasma concentration (Cmax) of Saroglitazar
| ng/mL | Saroglitazar Magnesium 1 mg | Saroglitazar Magnesium 2 mg | Saroglitazar Magnesium 4 mg |
|---|---|---|---|
| Pharmacokinetics of Saroglitazar Magnesium: Maximum Plasma Concentration (Cmax) | 65.034 ± 17.579 | 98.995 ± 77.189 | 219.475 ± 111.521 |
Time to reach maximum plasma concentration (Tmax) of saroglitazar
| hours | Saroglitazar Magnesium 1 mg | Saroglitazar Magnesium 2 mg | Saroglitazar Magnesium 4 mg |
|---|---|---|---|
| Time to Reach Maximum Plasma Concentration (Tmax) | 0.920 (0.500 to 1.020) | 1.500 (1.000 to 3.000) | 0.990 (0.500 to 2.080) |
Terminal Half-life (t1/2) of saroglitazar
| hour | Saroglitazar Magnesium 1 mg | Saroglitazar Magnesium 2 mg | Saroglitazar Magnesium 4 mg |
|---|---|---|---|
| Terminal Half-life (t1/2) | 6.040 ± 1.314 | 6.597 ± 4.217 | 5.429 ± 1.509 |
Area under the curve from the time of dosing to the last measurable concentration for saroglitazar
| hr*ng/mL | Saroglitazar Magnesium 1 mg | Saroglitazar Magnesium 2 mg | Saroglitazar Magnesium 4 mg |
|---|---|---|---|
| Area Under the Curve From the Time of Dosing to the Last Measurable Concentration (AUC0-t) | 171.064 ± 45.818 | 301.227 ± 202.061 | 667.646 ± 175.024 |
Area under the curve from the time of dosing to the infinity (AUC 0-inf) for Saroglitazar
| hr*ng/mL | Saroglitazar Magnesium 1 mg | Saroglitazar Magnesium 2 mg | Saroglitazar Magnesium 4 mg |
|---|---|---|---|
| Area Under the Curve From the Time of Dosing to the Infinity (AUC 0-inf) | 167.735 ± 45.322 | 305.532 ± 203.074 | 652.497 ± 169.565 |
Elimination rate constant (λz) for saroglitazar
| per hour | Saroglitazar Magnesium 1 mg | Saroglitazar Magnesium 2 mg | Saroglitazar Magnesium 4 mg |
|---|---|---|---|
| Elimination Rate Constant (λz) | 0.119 ± 0.027 | 0.129 ± 0.047 | 0.136 ± 0.035 |
Apparent volume of distribution (Vd/F) for Saroglitazar
| mL | Saroglitazar Magnesium 1 mg | Saroglitazar Magnesium 2 mg | Saroglitazar Magnesium 4 mg |
|---|---|---|---|
| Apparent Volume of Distribution (Vd/F) | 49788.200 ± 18040.188 | 81341.167 ± 72030.406 | 53772.143 ± 17575.770 |
Apparent clearance (CL/F) for Saroglitazar
| mL/hour | Saroglitazar Magnesium 1 mg | Saroglitazar Magnesium 2 mg | Saroglitazar Magnesium 4 mg |
|---|---|---|---|
| Apparent Clearance (CL/F) | 5969.472 ± 2502.313 | 8030.060 ± 2356.620 | 6972.059 ± 1890.090 |
Quality of life will be assessed by the Short-Form 36 Health Survey The SF-36 is a multi-purpose, short-form health survey with 36 questions. It yields an 8-scale profile of functional health and well-being scores (domains) as well as psychometrically based physical and mental health summary measures. The SF-36 taps 8 health concepts: physical functioning, bodily pain, physical role functioning, emotional role functioning, emotional well-being, social functioning, vitality, and general health perceptions. The 8 scales are further summarized to 2 distinct higher-ordered clusters: the PCS and mental composite t-score (MCS). The range for all 8 domains as well as for the composite t-scores is from 0 to 100 with 100 as best possible health status and 0 as worst health status.
| units on a scale | Saroglitazar Magnesium 1 mg | Saroglitazar Magnesium 2 mg | Saroglitazar Magnesium 4 mg | Placebo |
|---|---|---|---|---|
| Change in Quality of Life Assessed by the Short-Form 36 Health Survey | -1.7 ± 7.24 | -2.2 ± 7.57 | -3.8 ± 10.77 | -1.0 ± 6.16 |
Number of participants with adverse events
| participants | Saroglitazar Magnesium 1 mg | Saroglitazar Magnesium 2 mg | Saroglitazar Magnesium 4 mg | Placebos |
|---|---|---|---|---|
| Safety and Tolerability of Saroglitazar Magnesium | 13 | 13 | 14 | 19 |
Collected over 16 Weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Saroglitazar Magnesium 1 mg | 0/26 (0%) | 1/26 (3.8%) | 7/26 (26.9%) |
| Saroglitazar Magnesium 2 mg | 0/25 (0%) | 0/25 (0%) | 6/25 (24%) |
| Saroglitazar Magnesium 4 mg | 0/27 (0%) | 1/27 (3.7%) | 3/27 (11.1%) |
| Placebos | 0/28 (0%) | 0/28 (0%) | 5/28 (17.9%) |
| Event | Saroglitazar Magnesium 1 mg | Saroglitazar Magnesium 2 mg | Saroglitazar Magnesium 4 mg | Placebos |
|---|---|---|---|---|
| UreterolithiasisRenal and urinary disorders | 1/26 | 0/25 | 0/27 | 0/28 |
| Mental Status ChangePsychiatric disorders | 0/26 | 0/25 | 1/27 | 0/28 |
| Event | Saroglitazar Magnesium 1 mg | Saroglitazar Magnesium 2 mg | Saroglitazar Magnesium 4 mg | Placebos |
|---|---|---|---|---|
| HeadacheNervous system disorders | 3/26 | 1/25 | 1/27 | 0/28 |
| AnemiaBlood and lymphatic system disorders | 0/26 | 2/25 | 0/27 | 0/28 |
| Abdominal painGastrointestinal disorders | 0/26 | 2/25 | 0/27 | 0/28 |
| Upper respiratory tract infectionInfections and infestations | 1/26 | 2/25 | 2/27 | 0/28 |
| DiarrhoeaGastrointestinal disorders | 2/26 | 1/25 | 0/27 | 1/28 |
| CoughRespiratory, thoracic and mediastinal disorders | 2/26 | 0/25 | 1/27 | 0/28 |
| Urinary tract infectionInfections and infestations | 0/26 | 0/25 | 1/27 | 2/28 |
| HaematuriaRenal and urinary disorders | 1/26 | 0/25 | 1/27 | 2/28 |
| FlatulenceGastrointestinal disorders | 0/26 | 0/25 | 0/27 | 2/28 |
| Age, Continuous(Years) | Saroglitazar Magnesium 1 mg | Saroglitazar Magnesium 2 mg | Saroglitazar Magnesium 4 mg | Placebos | Total |
|---|---|---|---|---|---|
| Mean | 51.1 ± 12.89 | 47.9 ± 10.44 | 49 ± 10.97 | 48.7 ± 10.46 | 49.2 ± 11.13 |
| Sex: Female, Male(Participants) | Saroglitazar Magnesium 1 mg | Saroglitazar Magnesium 2 mg | Saroglitazar Magnesium 4 mg | Placebos | Total |
|---|---|---|---|---|---|
| Female | 13 | 12 | 12 | 13 | 50 |
| Male | 13 | 13 | 15 | 15 | 56 |
| Ethnicity (NIH/OMB)(Participants) | Saroglitazar Magnesium 1 mg | Saroglitazar Magnesium 2 mg | Saroglitazar Magnesium 4 mg | Placebos | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 10 | 8 | 12 | 13 | 43 |
| Not Hispanic or Latino | 16 | 17 | 15 | 15 | 63 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Saroglitazar Magnesium 1 mg | Saroglitazar Magnesium 2 mg | Saroglitazar Magnesium 4 mg | Placebos | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 0 | 0 | 1 |
| Asian | 3 | 3 | 3 | 3 | 12 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| White | 22 | 21 | 24 | 24 | 91 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 0 | 1 | 2 |
| Body Mass Index(kg/m^2) | Saroglitazar Magnesium 1 mg | Saroglitazar Magnesium 2 mg | Saroglitazar Magnesium 4 mg | Placebos | Total |
|---|---|---|---|---|---|
| Mean | 33.630 ± 4.2451 | 35.702 ± 8.5653 | 32.489 ± 5.1611 | 33.809 ± 4.4599 | 33.875 ± 5.8374 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Apr 2017 to primary completion in Aug 2019, 28 months.
Results were first posted in Oct 2024, 5 years 2 months after primary completion.
Of 132 industry-sponsored phase 2 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's 28 months is above that.
Counting every sponsor, half of 185 studies reached it within 26 months; a quarter within 16 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Saroglitazar
Non-alcoholic Fatty Liver Disease →